These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 19591631)

  • 1. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.
    Heimberger AB; Sampson JH
    Expert Opin Biol Ther; 2009 Aug; 9(8):1087-98. PubMed ID: 19591631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
    Sampson JH; Archer GE; Mitchell DA; Heimberger AB; Bigner DD
    Semin Immunol; 2008 Oct; 20(5):267-75. PubMed ID: 18539480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas.
    Del Vecchio CA; Li G; Wong AJ
    Expert Rev Vaccines; 2012 Feb; 11(2):133-44. PubMed ID: 22309662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
    Paff M; Alexandru-Abrams D; Hsu FP; Bota DA
    Hum Vaccin Immunother; 2014; 10(11):3322-31. PubMed ID: 25625931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.
    Schmittling RJ; Archer GE; Mitchell DA; Heimberger A; Pegram C; Herndon JE; Friedman HS; Bigner DD; Sampson JH
    J Immunol Methods; 2008 Nov; 339(1):74-81. PubMed ID: 18775433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
    Sampson JH; Heimberger AB; Archer GE; Aldape KD; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling RJ; Shi W; Vredenburgh JJ; Bigner DD
    J Clin Oncol; 2010 Nov; 28(31):4722-9. PubMed ID: 20921459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.
    Chistiakov DA; Chekhonin IV; Chekhonin VP
    Eur J Pharmacol; 2017 Sep; 810():70-82. PubMed ID: 28583430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospect of rindopepimut in the treatment of glioblastoma.
    Elsamadicy AA; Chongsathidkiet P; Desai R; Woroniecka K; Farber SH; Fecci PE; Sampson JH
    Expert Opin Biol Ther; 2017 Apr; 17(4):507-513. PubMed ID: 28274144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.
    Sampson JH; Archer GE; Mitchell DA; Heimberger AB; Herndon JE; Lally-Goss D; McGehee-Norman S; Paolino A; Reardon DA; Friedman AH; Friedman HS; Bigner DD
    Mol Cancer Ther; 2009 Oct; 8(10):2773-9. PubMed ID: 19825799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
    Swartz AM; Li QJ; Sampson JH
    Immunotherapy; 2014; 6(6):679-90. PubMed ID: 25186601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting EGFRvIII for glioblastoma multiforme.
    Yang J; Yan J; Liu B
    Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFRvIII-targeted vaccination therapy of malignant glioma.
    Choi BD; Archer GE; Mitchell DA; Heimberger AB; McLendon RE; Bigner DD; Sampson JH
    Brain Pathol; 2009 Oct; 19(4):713-23. PubMed ID: 19744042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The epidermal growth factor variant III peptide vaccine for treatment of malignant gliomas.
    Li G; Mitra S; Wong AJ
    Neurosurg Clin N Am; 2010 Jan; 21(1):87-93. PubMed ID: 19944969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
    Sampson JH; Aldape KD; Archer GE; Coan A; Desjardins A; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling R; Shi W; Vredenburgh JJ; Bigner DD; Heimberger AB
    Neuro Oncol; 2011 Mar; 13(3):324-33. PubMed ID: 21149254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination epidermal growth factor receptor variant III peptide-pulsed dendritic cell vaccine with miR-326 results in enhanced killing on EGFRvIII-positive cells.
    Li J; Wang F; Wang G; Sun Y; Cai J; Liu X; Zhang J; Lu X; Li Y; Chen M; Chen L; Jiang C
    Oncotarget; 2017 Apr; 8(16):26256-26268. PubMed ID: 28412740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma.
    Babu R; Adamson DC
    Core Evid; 2012; 7():93-103. PubMed ID: 23055947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
    Londhe VY; Date V
    Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination in the immunotherapy of glioblastoma.
    Kong Z; Wang Y; Ma W
    Hum Vaccin Immunother; 2018 Feb; 14(2):255-268. PubMed ID: 29087782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.